Spectral Medical’s Study Highlights High-Risk Septic Shock Subgroup, Bolstering PMX Therapy Rationale

Spectral Medical ( (TSE:EDT) ) has shared an update.

Spectral Medical announced the publication of a study in Critical Care Explorations that identifies endotoxic septic shock (ESS) as a high-risk subgroup with a significantly higher mortality rate, strengthening the rationale for its PMX therapy. The study’s findings support Spectral’s theranostic strategy of combining EAA diagnostics with PMX therapy, potentially enhancing its market positioning and supporting its upcoming FDA submission for commercialization in the U.S.

The most recent analyst rating on (TSE:EDT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Spectral Medical stock, see the TSE:EDT Stock Forecast page.

Spark’s Take on TSE:EDT Stock

According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.

Spectral Medical’s overall stock score is primarily influenced by its challenging financial performance, which poses significant risks. However, recent positive corporate events, including promising trial results and progress towards FDA approval, provide potential upside. Technical analysis and valuation factors offer a neutral to slightly negative outlook.

To see Spark’s full report on TSE:EDT stock, click here.

More about Spectral Medical

Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock. The company’s primary products include the PMX hemoadsorption device, which removes endotoxin from the bloodstream, and the FDA-cleared Endotoxin Activity Assay (EAA™) for diagnosing endotoxin levels in blood. Spectral’s market focus includes obtaining U.S. FDA approval for its products, which are already approved in Japan, Europe, and Canada.

Average Trading Volume: 172,255

Technical Sentiment Signal: Buy

Current Market Cap: C$465.9M

For detailed information about EDT stock, go to TipRanks’ Stock Analysis page.